Vanda Pharmaceuticals | VNDA - Frais De Vente Et D'Administration





Frais De Vente Et D'Administration Changement Date
Acadia Pharmaceuticals USD 160.79M 14.06M 2026-03
Agios Pharmaceuticals USD 38.46M 4.51M 2026-03
Akebia Therapeutics USD 23.53M 3.19M 2025-12
Alnylam Pharmaceuticals USD 282.51M 2.55M 2026-03
Anika Therapeutics USD 10.01M 14K 2025-12
Arrowhead Research USD 41.74M 4.28M 2026-03
AstraZeneca USD 5.06B 455M 2026-03
Bristol-Myers Squibb USD 1.62B 564M 2026-03
Eli Lilly USD 2.93B 198M 2026-03
Enanta Pharmaceuticals USD -1.05 0.31 2024-12
Esperion Therapeutics USD 39.42M 456K 2025-12
Halozyme Therapeutics USD 46.29M 18.35M 2026-03
Heron Therapeutics USD 23.74M 605K 2025-12
Insmed USD 247.26M 34.78M 2026-03
J&J USD 6.03B 719M 2026-03
Lexicon Pharmaceuticals USD 3.98M 195K 2025-12
Ligand Pharmaceuticals USD 20.84M 4.19M 2026-03
Merck USD 2.67B 180M 2026-03
Minerva Neurosciences USD 2.48M 58.79K 2024-09
Moderna USD 173M 135M 2026-03
Novartis USD 3.14B 296M 2026-03
Pfizer USD 2.92B 1.16B 2026-03
PTC Therapeutics USD 73.89M 13.31M 2026-03
Puma Biotechnology USD 16.82M 8.15M 2024-09
Sangamo BioSciences USD 9.64M 1.83M 2024-06
Sanofi EUR 2.33B 419M 2026-03
Takeda JPY 292B 9.21B 2026-03
Teva Pharmaceutical Industries USD 1000M 120M 2026-03
Ultragenyx Pharmaceutical USD 88M 1000K 2026-03
Vanda Pharmaceuticals USD 39.28M 1.71M 2024-12
Veracyte USD 50.84M 7.53M 2026-03